Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins

DMM Disease Models and Mechanisms

Volumn 7, Issue 10, 2014, Pages 1175-1184

  Jackrel, Meredith E ^a   Shorter, James ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disaggregase; FUS; Hsp104; Neurodegeneration; TDP 43; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; HEAT SHOCK PROTEIN 104; PROTEIN; RNA BINDING PROTEIN; HEAT SHOCK PROTEIN; HSP104 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN TOXICITY; DEGENERATIVE DISEASE; ENZYME SPECIFICITY; FRONTOTEMPORAL DEMENTIA; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; NERVE DEGENERATION; PARKINSON DISEASE; PRION; PROTEIN AGGREGATION; SACCHAROMYCES CEREVISIAE; WILD TYPE; GENETICS; MUTATION;

ALPHA-SYNUCLEIN; HEAT-SHOCK PROTEINS; MUTATION; NEURODEGENERATIVE DISEASES; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84907558479     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.016113     Document Type: Article

References (58)

1. Bendor, J. T., Logan, T. P. and Edwards, R. H. (2013). The function of α-synuclein. Neuron 79, 1044-1066.
2. Cashikar, A. G., Duennwald, M. and Lindquist, S. L. (2005). A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104. J. Biol. Chem. 280, 23869-23875.
3. Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Crowther, R. A. and Goedert, M. (2004). Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576, 363-368.
4. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E. and Lansbury, P. T., Jr (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576.
5. Couthouis, J., Hart, M. P., Shorter, J., DeJesus-Hernandez, M., Erion, R., Oristano, R., Liu, A. X., Ramos, D., Jethava, N., Hosangadi, D. et al. (2011). A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. USA 108, 20881-20890.
6. Couthouis, J., Hart, M. P., Erion, R., King, O. D., Diaz, Z., Nakaya, T., Ibrahim, F., Kim, H. J., Mojsilovic-Petrovic, J., Panossian, S. et al. (2012). Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 21, 2899-2911.
7. Cushman, M., Johnson, B. S., King, O. D., Gitler, A. D. and Shorter, J. (2010). Prion-like disorders: blurring the divide between transmissibility and infectivity. J. Cell Sci. 123, 1191-1201.
8. Cushman-Nick, M., Bonini, N. M. and Shorter, J. (2013). Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. PLoS Genet. 9, e1003781.
9. DeSantis, M. E. and Shorter, J. (2012). Hsp104 drives "protein-only" positive selection of Sup35 prion strains encoding strong [PSI(+)]. Chem. Biol. 19, 1400-1410.
10. DeSantis, M. E., Leung, E. H., Sweeny, E. A., Jackrel, M. E., Cushman-Nick, M., Neuhaus-Follini, A., Vashist, S., Sochor, M. A., Knight, M. N. and Shorter, J. (2012). Operational plasticity enables Hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151, 778-793.
11. Dobson, C. M. (2003). Protein folding and misfolding. Nature 426, 884-890.
12. Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M. E., Mackenzie, I. R., Capell, A., Schmid, B. et al. (2010). ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 29, 2841-2857.
13. Doyle, S. M., Shorter, J., Zolkiewski, M., Hoskins, J. R., Lindquist, S. and Wickner, S. (2007). Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat. Struct. Mol. Biol. 14, 114-122.
14. Duennwald, M. L., Echeverria, A. and Shorter, J. (2012). Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol. 10, e1001346.
15. Fredenburg, R. A., Rospigliosi, C., Meray, R. K., Kessler, J. C., Lashuel, H. A., Eliezer, D. and Lansbury, P. T., Jr (2007). The impact of the E46K mutation on the properties of α-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107-7118.
16. Garcia, D. M. and Jarosz, D. F. (2014). Rebels with a cause: molecular features and physiological consequences of yeast prions. FEMS Yeast Res. 14, 136-147.
17. Gietz, R. D. and Schiestl, R. H. (2007). High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 31-34.
18. Gitcho, M. A., Baloh, R. H., Chakraverty, S., Mayo, K., Norton, J. B., Levitch, D., Hatanpaa, K. J., White, C. L., III, Bigio, E. H., Caselli, R. et al. (2008). TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 63, 535-538.
19. Glover, J. R. and Lindquist, S. (1998). Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 94, 73-82.
20. Guo, W., Chen, Y., Zhou, X., Kar, A., Ray, P., Chen, X., Rao, E. J., Yang, M., Ye, H., Zhu, L. et al. (2011). An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Struct. Mol. Biol. 18, 822-830.
21. Hoskins, J. R., Singh, S. K., Maurizi, M. R. and Wickner, S. (2000). Protein binding and unfolding by the chaperone ClpA and degradation by the protease ClpAP. Proc. Natl. Acad. Sci. USA 97, 8892-8897.
22. Huang, E. J., Zhang, J., Geser, F., Trojanowski, J. Q., Strober, J. B., Dickson, D. W., Brown, R. H., Jr, Shapiro, B. E. and Lomen-Hoerth, C. (2010). Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol. 20, 1069-1076.
23. Jackrel, M. E. and Shorter, J. (2014). Reversing deleterious protein aggregation with re-engineered protein disaggregases. Cell Cycle 13, 1379-1383.
24. Jackrel, M. E., DeSantis, M. E., Martinez, B. A., Castellano, L. M., Stewart, R. M., Caldwell, K. A., Caldwell, G. A. and Shorter, J. (2014). Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170-182.
25. Johnson, B. S., McCaffery, J. M., Lindquist, S. and Gitler, A. D. (2008). A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA 105, 6439-6444.
26. Johnson, B. S., Snead, D., Lee, J. J., McCaffery, J. M., Shorter, J. and Gitler, A. D. (2009). TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284, 20329-20339.
27. Jones, D. R., Moussaud, S. and McLean, P. (2014). Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord 7, 33-51.
28. Kim, H. J., Raphael, A. R., LaDow, E. S., McGurk, L., Weber, R. A., Trojanowski, J. Q., Lee, V. M., Finkbeiner, S., Gitler, A. D. and Bonini, N. M. (2014). Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. 46, 152-160.
29. King, O. D., Gitler, A. D. and Shorter, J. (2012). The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462, 61-80.
30. Lagier-Tourenne, C., Polymenidou, M. and Cleveland, D. W. (2010). TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 19 R1, R46-R64.
31. Lo Bianco, C., Shorter, J., Régulier, E., Lashuel, H., Iwatsubo, T., Lindquist, S. and Aebischer, P. (2008). Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J. Clin. Invest. 118, 3087-3097.
32. Mackenzie, I. R. A. and Neumann, M. (2012). FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res. 1462, 40-43.
33. Newby, G. A. and Lindquist, S. (2013). Blessings in disguise: biological benefits of prion-like mechanisms. Trends Cell Biol. 23, 251-259.
34. Olzscha, H., Schermann, S. M., Woerner, A. C., Pinkert, S., Hecht, M. H., Tartaglia, G. G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F. U. and Vabulas, R. M. (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67-78.
35. Outeiro, T. F. and Lindquist, S. (2003). Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772-1775.
36. Parsell, D. A., Sanchez, Y., Stitzel, J. D. and Lindquist, S. (1991). Hsp104 is a highly conserved protein with two essential nucleotide-binding sites. Nature 353, 270-273.
37. Parsell, D. A., Kowal, A. S., Singer, M. A. and Lindquist, S. (1994). Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372, 475-478.
38. Pearl, L. H. and Prodromou, C. (2006). Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271-294.
39. Pesiridis, G. S., Lee, V. M. and Trojanowski, J. Q. (2009). Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 18 R2, R156-R162.
40. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
41. Qiu, H., Lee, S., Shang, Y., Wang, W. Y., Au, K. F., Kamiya, S., Barmada, S. J., Finkbeiner, S., Lui, H., Carlton, C. E. et al. (2014). ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 124, 981-999.
42. Raviol, H., Bukau, B. and Mayer, M. P. (2006). Human and yeast Hsp110 chaperones exhibit functional differences. FEBS Lett. 580, 168-174.
43. Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D. and Giusti, P. (2004). Alpha-synuclein and Parkinson's disease. FASEB J. 18, 617-626.
44. Robberecht, W. and Philips, T. (2013). The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248-264.
45. Sanchez, Y. and Lindquist, S. L. (1990). HSP104 required for induced thermotolerance. Science 248, 1112-1115.
46. Schirmer, E. C., Homann, O. R., Kowal, A. S. and Lindquist, S. (2004). Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region. Mol. Biol. Cell 15, 2061-2072.
47. Shorter, J. (2008). Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 16, 63-74.
48. Shorter, J. (2011). The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS ONE 6, e26319.
49. Shorter, J. and Lindquist, S. (2004). Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304, 1793-1797.
50. Shorter, J. and Lindquist, S. (2006). Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol. Cell 23, 425-438.
51. Shorter, J. and Lindquist, S. (2008). Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J. 27, 2712-2724.
52. Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E. et al. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672.
53. Sun, Z., Diaz, Z., Fang, X., Hart, M. P., Chesi, A., Shorter, J. and Gitler, A. D. (2011). Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 9, e1000614.
54. Taipale, M., Jarosz, D. F. and Lindquist, S. (2010). HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11, 515-528.
55. Torrente, M. P. and Shorter, J. (2013). The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. Prion 7, 457-463.
56. Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P. et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
57. Vashist, S., Cushman, M. and Shorter, J. (2010). Applying Hsp104 to proteinmisfolding disorders. Biochem. Cell Biol. 88, 1-13.
58. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B. et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.